http://medicalxpress.com/ en-us Medical Xpress provides the latest news from American Society of Hematology The increasing cost of treatments for chronic myeloid leukemia (CML) in the United States has reached unsustainably high levels and may be leaving many patients under- or untreated because they cannot afford care, according to a Blood Forum article supported by nearly 120 CML experts from more than 15 countries on five continents and published online today in Blood, the Journal of the American Society of Hematology (ASH). Blood Forum articles are a new feature in the journal that present well documented opinions on controversial topics and provide a sounding board for current subjects of importance to the science and practice of hematology. http://medicalxpress.com/news/2013-04-leukemia-experts-high-treatment-patients.html Cancer Thu, 25 Apr 2013 11:07:31 EST news286106843 A new study on how the progression of acute lymphocytic leukemia (ALL) is influenced by the bone marrow environment has demonstrated for the first time that targeting a specialized protein known as osteopontin (OPN) may be an effective strategy to increase the efficacy of chemotherapy in patients with this type of blood cancer. Study data were published online today in Blood, the Journal of the American Society of Hematology (ASH). http://medicalxpress.com/news/2013-04-key-bone-marrow-protein-potential.html Cancer Mon, 15 Apr 2013 12:44:09 EST news285248642 Transplants of blood-forming stem cells from umbilical cord blood may be an effective alternative to transplants of matched donor bone marrow stem cells to treat children with a rare, debilitating disease known as Hurler's syndrome (HS), according to results of a study published online today in Blood, the Journal of the American Society of Hematology (ASH). http://medicalxpress.com/news/2013-03-cord-blood-effective-alternative-donor.html Medical research Thu, 14 Mar 2013 11:03:12 EST news282477785 While advancements in cancer treatment over the last several decades have improved patient survival rates for certain cancers, some patients remain at risk of developing treatment-related leukemia, according to results of a study published online in Blood, the Journal of the American Society of Hematology (ASH). http://medicalxpress.com/news/2013-02-leukemia-cancer-chemotherapy-persists.html Cancer Thu, 14 Feb 2013 11:50:03 EST news280063697 Data published online today in Blood, the Journal of the American Society of Hematology (ASH) describe the work of an ASH international clinical network collaborative focused on modernizing treatment protocols for patients in the developing world with acute promyeloctyic leukemia (APL) that has drastically improved cure rates in patients in Central and South America, achieving comparable outcomes to those observed in patients in the United States and in Europe. http://medicalxpress.com/news/2013-01-ash-international-clinical-collaboration-replicates.html Cancer Mon, 14 Jan 2013 10:56:03 EST news277383345 New research examining the role of race and ethnicity in an individual's decision to become a donor for hematopoietic cell transplantation (HCT) identifies several factors associated with varied participation rates in national donor registries across racial/ethnic groups. Results of this first-of-its-kind study are published online today in Blood, the Journal of the American Society of Hematology (ASH). http://medicalxpress.com/news/2012-12-cultural-social-factors-barriers-minority.html Other Thu, 20 Dec 2012 12:26:19 EST news275228760 A survey highlighting the correlation between today's cutting edge medical research and the National Institutes of Health (NIH) funding was released today at the 54th Annual Meeting of the American Society of Hematology (ASH), the preeminent medical meeting for physicians and scientists in hematology that draws more than 20,000 attendees from around the world. The survey, representing responses from 1,040 abstract presenters from the U.S. and abroad, demonstrates how critical NIH funding has been to the success of science and medicine. http://medicalxpress.com/news/2012-12-survey-breakthrough-medical-heavily-nih.html Other Mon, 10 Dec 2012 10:11:47 EST news274356689 Researchers have demonstrated that combination therapy with PU-H71 and ruxolitinib increases the durability and effectiveness of a treatment that had previously shown limited utility for patients with myelofibrosis. http://medicalxpress.com/news/2012-12-combination-therapy-jak2-hsp90-inhibitors.html Cancer Sun, 09 Dec 2012 12:00:03 EST news274274558 Encouraging safety and efficacy data on novel and emerging therapies presented at the 54th Annual Meeting of the American Society of Hematology (ASH) signal an important step forward in the development of treatment strategies for patients with hard-to-treat leukemia, myeloma, and myelofibrosis. http://medicalxpress.com/news/2012-12-therapeutic-agents-patients-hard-to-treat-blood.html Cancer Sun, 09 Dec 2012 11:50:04 EST news274274478 New research shows that the addition of the oral anti-cancer agent vorinostat to standard therapy given before, during, and after hematopoietic stem cell transplantation (HSCT) may safely reduce the incidence and severity of a challenging complication called graft-versus-host disease (GVHD). http://medicalxpress.com/news/2012-12-histone-deacetylases-strategy-graft-host.html Medical research Sun, 09 Dec 2012 11:50:02 EST news274275657 Studies of stem cell biology and transplant approaches presented today at the 54th Annual Meeting of the American Society of Hematology (ASH) illustrate how the use of advanced modeling techniques is optimizing stem cells to treat patients with blood disorders, as well as the potential of enhanced treatment strategies to improve the success rate of hematopoietic stem cell (HSC) transplantation for these patients. http://medicalxpress.com/news/2012-12-stem-cell-transplant-strategies-outcomes.html Medical research Sun, 09 Dec 2012 11:40:25 EST news274275601 In the first randomized clinical trial assessing the proper target hematocrit level, or percentage of red blood cells that should be maintained in patients with polycythemia vera (PV), researchers have concluded that the current recommendation to maintain a hematocrit level of less than 45 percent is associated with a lower risk of thrombosis compared with a less aggressive treatment strategy of maintaining a hematocrit level between 45 and 50 percent. http://medicalxpress.com/news/2012-12-large-scale-trial-intensity-cytoreductive-therapy.html Medical research Sun, 09 Dec 2012 03:50:01 EST news274244491 Research identifying genetic factors that affect survival of patients with blood cancers and evaluating the effectiveness of modified treatment strategies to improve outcomes while reducing toxicity will be presented today at the 54th Annual Meeting of the American Society of Hematology (ASH). http://medicalxpress.com/news/2012-12-genetics-treatment-outcomes-toxicity.html Cancer Sun, 09 Dec 2012 03:30:02 EST news274244343 Researchers have identified specific genetic factors that are associated with heart failure in patients who have undergone hematopoietic stem cell transplantation (HCT) for blood cancer. http://medicalxpress.com/news/2012-12-genetic-susceptibility-anthracycline-related-congestive-heart.html Medical research Sun, 09 Dec 2012 03:20:01 EST news274244222 New research suggests that the presence of a specific genetic marker, known as WT1 SNP rs16754, may be associated with reduced toxicity from chemotherapy in African-American and Asian children with acute myeloid leukemia (AML). http://medicalxpress.com/news/2012-12-genotype-treatment-mortality-trm-african-american.html Cancer Sun, 09 Dec 2012 03:10:02 EST news274244165